Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer

Medical Oncology

Volumn 31, Issue 3, 2014, Pages

  Miger, Jasmine ^a   Holmqvist, Annika ^a   Sun, Xiao Feng ^a   Albertsson, Maria ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Capecitabine; Gastrointestinal cancer; Metronomic treatment; QoL; Response

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; PRODRUG;

ABSENCE OF SIDE EFFECTS; ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CECUM CANCER; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HEPATOBILIARY DISEASE; HUMAN; LIVER BIOPSY; LOW DRUG DOSE; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RADIODIAGNOSIS; RADIOFREQUENCY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UPPER GASTROINTESTINAL TRACT; DOSE RESPONSE; FOLLOW UP; GASTROINTESTINAL TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; PRODRUGS; PROGNOSIS; SURVIVAL RATE;

EID: 84898829186     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0870-2     Document Type: Article

References (6)

1. Hofheinz R-D, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012;13(6):579-88.
2. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22(22):4626-31.
3. Carstens H, Albertsson M. Successful treatment with low-dose capecitabine for disseminated esophageal adenocarcinoma. Acta Oncol. 2007;46(6):866-8.
4. Dahlberg M, Påhlman L, Bergström R, Glimelius B. Improved survival in patients with rectal cancer: a population-based register study. Br J Surg. 2013;85(4):515-20.
5. Dotan E, Browner I, Hurria A, Denlinger C. Challenges in the management of older patients with colon cancer. J Natl Compr Canc Netw. 2012;10(2):213-24.
6. Aparicio T, Jouve J-L, Teillet L, Gargot D, Subtil F, Le Brun-Ly V et al. Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-2002 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. J Clin Oncol. 2013;31(11):1464-70.